GC Wealth Management RIA LLC Acquires New Stake in Cue Biopharma, Inc. $CUE

Key Points

• GC Wealth Management RIA LLC acquired a new stake in Cue Biopharma, Inc. by purchasing 3,331,644 shares valued at approximately $2.27 million, representing 4.42% of the company's stock.
• Several other institutional investors, including Bank of America and Northern Trust, have significantly boosted their holdings in Cue Biopharma in recent quarters, highlighting increased interest in the company.
• Cue Biopharma recently reported better-than-expected quarterly earnings with an EPS of ($0.09), exceeding analysts' estimates by $0.04, and generated revenue of $2.95 million, surpassing expectations of $2.00 million.

GC Wealth Management RIA LLC acquired a new stake in shares of Cue Biopharma, Inc. (NASDAQ:CUE - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 3,331,644 shares of the company's stock, valued at approximately $2,273,000. GC Wealth Management RIA LLC owned 4.42% of Cue Biopharma as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Bank of America Corp DE boosted its holdings in Cue Biopharma by 35.6% during the 4th quarter. Bank of America Corp DE now owns 324,315 shares of the company's stock valued at $354,000 after acquiring an additional 85,113 shares during the period. Northern Trust Corp boosted its holdings in Cue Biopharma by 50.5% during the 4th quarter. Northern Trust Corp now owns 208,206 shares of the company's stock valued at $227,000 after acquiring an additional 69,892 shares during the period. Chicago Partners Investment Group LLC purchased a new position in Cue Biopharma during the 1st quarter valued at $82,000. Finally, Jane Street Group LLC boosted its holdings in Cue Biopharma by 145.9% during the 4th quarter. Jane Street Group LLC now owns 63,767 shares of the company's stock valued at $70,000 after acquiring an additional 37,832 shares during the period. Hedge funds and other institutional investors own 35.04% of the company's stock.

Cue Biopharma Price Performance

CUE opened at $0.71 on Monday. The business has a fifty day moving average of $0.79 and a 200 day moving average of $0.76. Cue Biopharma, Inc. has a 52-week low of $0.45 and a 52-week high of $1.99. The company has a quick ratio of 1.60, a current ratio of 1.60 and a debt-to-equity ratio of 0.01. The stock has a market cap of $54.55 million, a P/E ratio of -1.27 and a beta of 1.58.

Cue Biopharma (NASDAQ:CUE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.04. The company had revenue of $2.95 million during the quarter, compared to analysts' expectations of $2.00 million. Cue Biopharma had a negative return on equity of 230.13% and a negative net margin of 469.35%. As a group, sell-side analysts anticipate that Cue Biopharma, Inc. will post -0.76 EPS for the current year.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.

Want to see what other hedge funds are holding CUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cue Biopharma, Inc. (NASDAQ:CUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.